Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA. Smit EF, et al. Among authors: tsuchihashi z. Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. Lancet Oncol. 2024. PMID: 38547891 Clinical Trial.
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit EF, de Langen AJ, Pérol M, Pons-Tostivint E, Novello S, Hayashi H, Shimizu J, Kim DW, Kuo CH, Yang JC, Pereira K, Cheng FC, Taguchi A, Cheng Y, Feng W, Tsuchihashi Z, Jänne PA. Goto K, et al. Among authors: tsuchihashi z. J Clin Oncol. 2023 Nov 1;41(31):4852-4863. doi: 10.1200/JCO.23.01361. Epub 2023 Sep 11. J Clin Oncol. 2023. PMID: 37694347 Free PMC article. Clinical Trial.
Responsiveness to cetuximab without mutations in EGFR.
Tsuchihashi Z, Khambata-Ford S, Hanna N, Jänne PA. Tsuchihashi Z, et al. N Engl J Med. 2005 Jul 14;353(2):208-9. doi: 10.1056/NEJM200507143530218. N Engl J Med. 2005. PMID: 16014894 No abstract available.
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
Mendell J, Freeman DJ, Feng W, Hettmann T, Schneider M, Blum S, Ruhe J, Bange J, Nakamaru K, Chen S, Tsuchihashi Z, von Pawel J, Copigneaux C, Beckman RA. Mendell J, et al. Among authors: tsuchihashi z. EBioMedicine. 2015 Feb 12;2(3):264-71. doi: 10.1016/j.ebiom.2015.02.005. eCollection 2015 Mar. EBioMedicine. 2015. PMID: 26137564 Free PMC article. Clinical Trial.
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK. Lenz HJ, et al. Among authors: tsuchihashi z. J Clin Oncol. 2006 Oct 20;24(30):4914-21. doi: 10.1200/JCO.2006.06.7595. J Clin Oncol. 2006. PMID: 17050875 Clinical Trial.
Trastuzumab Deruxtecan With Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
Hamilton E, Galsky MD, Ochsenreither S, Del Conte G, Martín M, de Miguel MJ, Yu EY, Williams A, Gion M, Tan AR, Agrawal L, Rutten A, Machiels JP, Cresta S, Debruyne PR, Hennequin A, Moreno V, Minchom A, Valdes-Albini F, Petrylak D, Li L, Tsuchihashi Z, Suto F, Cheng FC, Kandil M, Barrios D, Hurvitz S. Hamilton E, et al. Among authors: tsuchihashi z. Clin Cancer Res. 2024 Oct 15. doi: 10.1158/1078-0432.CCR-24-1513. Online ahead of print. Clin Cancer Res. 2024. PMID: 39405343
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer.
Kapil A, Spitzmüller A, Brieu N, Haneder S, Shumilov A, Meier A, Cecchi F, Barkell A, Harder N, Mittermaier K, Hidalgo-Sastre A, Alleze R, Schick M, Schmidt G, Sade H, Tsuchihashi Z, Suto F, Gustavson M, Barrett JC, Carroll D. Kapil A, et al. Among authors: tsuchihashi z. Sci Rep. 2024 May 27;14(1):12129. doi: 10.1038/s41598-024-61957-9. Sci Rep. 2024. PMID: 38802399 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Sakamoto Y, Nishina T, Inaki K, Kuwahara Y, Wada N, Suto F, Arita T, Sugihara M, Tsuchihashi Z, Saito K, Kojima A, Yamaguchi K. Shitara K, et al. Among authors: tsuchihashi z. Nat Med. 2024 Jul;30(7):1933-1942. doi: 10.1038/s41591-024-02992-x. Epub 2024 May 14. Nat Med. 2024. PMID: 38745009 Free PMC article. Clinical Trial.
Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy.
Siroky BJ, Yin H, Dixon BP, Reichert RJ, Hellmann AR, Ramkumar T, Tsuchihashi Z, Bunni M, Dillon J, Bell PD, Sampson JR, Bissler JJ. Siroky BJ, et al. Among authors: tsuchihashi z. Am J Physiol Renal Physiol. 2014 Sep 1;307(5):F560-70. doi: 10.1152/ajprenal.00569.2013. Epub 2014 Jun 11. Am J Physiol Renal Physiol. 2014. PMID: 24920756 Free PMC article.
37 results